These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
173 related items for PubMed ID: 10590682
21. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis. Potze W, Arshad F, Adelmeijer J, Blokzijl H, van den Berg AP, Porte RJ, Lisman T. Br J Haematol; 2013 Dec; 163(5):666-73. PubMed ID: 24219333 [Abstract] [Full Text] [Related]
22. Evaluation of a new venom-based clotting assay of protein C. Cooper PC, Cooper SM, Goodfellow KJ, Hickey KP, Kitchen S, Makris M. Int J Lab Hematol; 2008 Oct; 30(5):437-43. PubMed ID: 19046320 [Abstract] [Full Text] [Related]
23. [Long-term treatment with low molecular weight heparin, of chronic disseminated intravascular coagulation]. García Fernández JR, López Berenguel F, Ais C. An Med Interna; 2003 Apr; 20(4):191-4. PubMed ID: 12768833 [Abstract] [Full Text] [Related]
24. Comparison of a fluorogenic anti-FXa assay with a central laboratory chromogenic anti-FXa assay for measuring LMWH activity in patient plasmas. Harris LF, Castro-López V, Jenkins PV, O'Donnell JS, Killard AJ. Thromb Res; 2011 Dec; 128(6):e125-9. PubMed ID: 21824646 [Abstract] [Full Text] [Related]
25. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time. Harenberg J, Giese C, Hagedorn A, Traeger I, Fenyvesi T. Semin Thromb Hemost; 2007 Jul; 33(5):503-7. PubMed ID: 17629847 [Abstract] [Full Text] [Related]
26. Test of the month: The chromogenic antifactor Xa assay. Gehrie E, Laposata M. Am J Hematol; 2012 Feb; 87(2):194-6. PubMed ID: 22081480 [Abstract] [Full Text] [Related]
27. A new chronometric assay to determine plasma antifactor Xa activity which is insensitive to the antithrombin activity of low molecular weight heparins. Dignac M, Gabaig AM, Cambus JP, Boneu B. Nouv Rev Fr Hematol (1978); 1994 Feb; 35(6):545-9. PubMed ID: 8152901 [Abstract] [Full Text] [Related]
28. Efficacy of low molecular weight heparin in a canine model of thromboplastin-induced acute disseminated intravascular coagulation. Mischke R, Fehr M, Nolte I. Res Vet Sci; 2005 Aug; 79(1):69-76. PubMed ID: 15894027 [Abstract] [Full Text] [Related]
30. Development and clinical evaluation of two chromogenic substrate methods for monitoring fondaparinux sodium. Klaeffling C, Piechottka G, Daemgen-von Brevern G, Mosch G, Mani H, Luxembourg B, Lindhoff-Last E. Ther Drug Monit; 2006 Jun; 28(3):375-81. PubMed ID: 16778722 [Abstract] [Full Text] [Related]
31. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective. Favaloro EJ, Bonar R, Aboud M, Low J, Sioufi J, Wheeler M, Lloyd J, Street A, Marsden K, RCPA QAP in Haematology. Lab Hematol; 2005 Jun; 11(3):157-62. PubMed ID: 16174600 [Abstract] [Full Text] [Related]
32. Heparin monitoring during cardiopulmonary bypass surgery using the one-step point-of-care whole blood anti-factor-Xa clotting assay heptest-POC-Hi. Hellstern P, Bach J, Simon M, Saggau W. J Extra Corpor Technol; 2007 Jun; 39(2):81-6. PubMed ID: 17672188 [Abstract] [Full Text] [Related]
33. Circulating activities during constant infusion of heparin or a low molecular weight derivative (enoxaparine): failure to demonstrate any circadian variations. Toulon P, Vitoux JF, Leroy C, Lecomte T, Roncato M, Motobashi Y, Aiach M, Fiessinger JN. Thromb Haemost; 1987 Dec 18; 58(4):1068-72. PubMed ID: 2832964 [Abstract] [Full Text] [Related]
34. Two sensitive and rapid chromogenic assays of fondaparinux sodium (Arixtra) in human plasma and other biological matrices. Paolucci F, Frasa H, Van Aarle F, Capdevla A, Clavies MC, van Dinther T, Donat F, Hendriks Y, van den Heuvel M, Nadal T, Lagrange F, Necciari J, Perez Y. Clin Lab; 2003 Dec 18; 49(9-10):451-60. PubMed ID: 14572200 [Abstract] [Full Text] [Related]
35. In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery. Kim YS, Murkin JM, Adams SJ. Heart Surg Forum; 2004 Dec 18; 7(6):E599-604. PubMed ID: 15769695 [Abstract] [Full Text] [Related]
36. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay. Kitchen S, Theaker J, Preston FE. Blood Coagul Fibrinolysis; 2000 Mar 18; 11(2):137-44. PubMed ID: 10759006 [Abstract] [Full Text] [Related]
37. Trial of low molecular weight heparin in the treatment of viper bites. Paul V, Pudoor A, Earali J, John B, Anil Kumar CS, Anthony T. J Assoc Physicians India; 2007 May 18; 55():338-42. PubMed ID: 17844693 [Abstract] [Full Text] [Related]
38. Comparison of three methods for measuring factor VIII levels in plasma. Chandler WL, Ferrell C, Lee J, Tun T, Kha H. Am J Clin Pathol; 2003 Jul 18; 120(1):34-9. PubMed ID: 12866370 [Abstract] [Full Text] [Related]
39. A new plastic collection tube made of polyethylene terephtalate is suitable for monitoring traditional anticoagulant therapy (oral anticoagulant, unfractionated heparin, and low molecular weight heparin). Toulon P, Ajzenberg N, Smahi M, Guillin MC. Thromb Res; 2007 Jul 18; 119(2):135-43. PubMed ID: 16426667 [Abstract] [Full Text] [Related]
40. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot. Ganter MT, Monn A, Tavakoli R, Genoni M, Klaghofer R, Furrer L, Honegger H, Hofer CK. Eur J Cardiothorac Surg; 2006 Aug 18; 30(2):278-84. PubMed ID: 16828293 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]